Abeona Therapeutics (NASDAQ:ABEO) Lifted to Hold at StockNews.com

StockNews.com upgraded shares of Abeona Therapeutics (NASDAQ:ABEO) from a sell rating to a hold rating in a report issued on Tuesday morning.

A number of other analysts have also recently commented on the company. HC Wainwright restated a buy rating and issued a $15.00 price target on shares of Abeona Therapeutics in a research report on Friday, July 12th. Cantor Fitzgerald decreased their target price on shares of Abeona Therapeutics from $28.00 to $21.00 and set an overweight rating on the stock in a research note on Thursday, May 16th. Finally, Stifel Nicolaus initiated coverage on shares of Abeona Therapeutics in a report on Thursday, May 30th. They issued a buy rating and a $21.00 target price for the company.

Abeona Therapeutics Price Performance

Shares of ABEO opened at $5.00 on Tuesday. The business has a fifty day moving average of $4.72 and a 200 day moving average of $5.57. The firm has a market capitalization of $204.82 million, a P/E ratio of -1.56 and a beta of 1.59. Abeona Therapeutics has a one year low of $3.05 and a one year high of $9.01.

Abeona Therapeutics (NASDAQ:ABEO) last issued its quarterly earnings data on Wednesday, May 15th. The biopharmaceutical company reported ($0.53) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.47) by ($0.06). Analysts expect that Abeona Therapeutics will post -1.81 EPS for the current fiscal year.

Institutional Investors Weigh In On Abeona Therapeutics

A number of hedge funds have recently made changes to their positions in the company. Simplify Asset Management Inc. bought a new stake in Abeona Therapeutics in the 2nd quarter worth approximately $1,732,000. Renaissance Technologies LLC increased its position in Abeona Therapeutics by 581.6% in the second quarter. Renaissance Technologies LLC now owns 503,293 shares of the biopharmaceutical company’s stock worth $2,134,000 after purchasing an additional 429,456 shares during the last quarter. Bank of New York Mellon Corp increased its position in Abeona Therapeutics by 2.0% in the second quarter. Bank of New York Mellon Corp now owns 121,453 shares of the biopharmaceutical company’s stock worth $515,000 after purchasing an additional 2,434 shares during the last quarter. Rosalind Advisors Inc. purchased a new stake in Abeona Therapeutics during the second quarter valued at $7,420,000. Finally, Western Standard LLC lifted its position in Abeona Therapeutics by 68.5% during the first quarter. Western Standard LLC now owns 1,361,489 shares of the biopharmaceutical company’s stock valued at $9,871,000 after purchasing an additional 553,377 shares during the last quarter. 80.56% of the stock is currently owned by hedge funds and other institutional investors.

About Abeona Therapeutics

Abeona Therapeutics Inc, a clinical-stage biopharmaceutical company, focuses on developing and delivering gene therapy products for severe and life-threatening rare diseases. The company's lead programs are EB-101 (gene-corrected skin grafts) for recessive dystrophic epidermolysis bullosa (RDEB); ABO-102, which are AAV based gene therapies for Sanfilippo syndrome type A; and ABO-101, an adeno-associated virus (AAV) based gene therapies for Sanfilippo syndrome type B.